Showing 2,021 - 2,040 results of 74,781 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 1.28s Refine Results
  1. 2021

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  2. 2022
  3. 2023
  4. 2024
  5. 2025
  6. 2026
  7. 2027
  8. 2028
  9. 2029
  10. 2030
  11. 2031
  12. 2032
  13. 2033
  14. 2034
  15. 2035
  16. 2036

    Evaluating competitive inhibition by gcn5-F221A using a synthetic pPHO5-yECitrine construct. by Amanda M. Lanza (168454)

    Published 2012
    “…Increasing expression of <i>gcn5-F221A</i> resulted in decreased mean fluorescence. …”
  17. 2037
  18. 2038

    PKCε activation induces aggrecan gene expression, decreases ADAMTS5, and detection of ADAMTS-5-depended cleavage of ECM aggrecan through upregulation of hsa-miR-377 expression. by Emmanouella Tsirimonaki (490707)

    Published 2013
    “…<p>(<b>A</b>) RT-PCR detected the relative expression of ACAN, MKI67, ADAMTS5 after treatment of NP cells with 1 μM ψεRACK (or vehicle) for indicated times and revealed that time-dependent activation of PKCε significantly increased the mRNA expression for aggrecan, while in an opposing manner decreased ADAMTS5; mRNA levels of the proliferation marker Ki67 became barely detectable after 8 hours of PKCε activation. …”
  19. 2039
  20. 2040